New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2013
07:06 EDTPG, CHD, PFEMore vitamin deals expected, WSJ reports
Procter & Gamble (PG), Pfizer (PFE) and Arm & Hammer (CHD) owner Church & Dwight Co. all acquired makers of dietary supplements last year. More deals are expected, as companies bet baby boomers and rising health-care costs will drive demand for products, reports the Wall Street Journal.Reference Link
News For PG;PFE;CHD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
10:00 EDTCHDOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:02 EDTPFEMerck KGaA, Pfizer initiate Phase III study with Avelumab
Subscribe for More Information
06:19 EDTCHDChurch & Dwight downgraded to Neutral from Buy at Goldman
Goldman downgraded Church & Dwight to Neutral and reduced its price target to $88 from $89 due to limited upside and increasing U.S. competition.
06:05 EDTPFEProvectus receives notice of allowance for PV-10 combined with other drugs
Subscribe for More Information
April 17, 2015
16:02 EDTPGProcter & Gamble raises quarterly dividend 3%
Subscribe for More Information
April 15, 2015
16:39 EDTPGHenkel, Revlon, Coty line up bids for Procter & Gamble beauty unit, Reuters says
According to sources, Henkel & Co (HENKY), Revlon (REV) and Coty (COTY) are lining up bids for parts of Procter & Gamble's (PG) beauty business, Reuters reports. Reference Link
08:04 EDTPFEPfizer: PALOMA-3 trial for IBRANCE met primary endpoint, trial stopped early
Subscribe for More Information
April 14, 2015
06:11 EDTPGProcter & Gamble CEO could step down as early as summer, WSJ reports
Procter & Gamble CEO A.G. Lafley and other senior executives have reportedly made comments in private meetings with Wall Street analysts and investors that Lafley could step down as early as this summer, The Wall Street Journal reports, citing sources who attended the meetings. Analysts believe Lafley could remain chairman for "another year or two" to help smooth a CEO transition. The company's next CEO, which is likely to be an internal candidate, is widely expected to be P&G executive David Taylor. Reference Link
April 13, 2015
15:12 EDTPFEMylan enters settlement, license agreement with Pfizer regarding Viagra
Mylan (MYL) announced that its subsidiaries Mylan Inc. and Mylan Pharmaceuticals have entered into a settlement and license agreement with Pfizer (PFE), Pfizer Limited and Pfizer Ireland Pharmaceuticals to settle patent litigation relating to Mylan's Abbreviated New Drug Application filed with the U.S. FDA for Sildenafil Citrate Tablets 25 mg, 50 mg, and 100 mg. This product is the generic version of Viagra, which is indicated to treat erectile dysfunction. Under the terms of the agreement, Mylan will be able to launch its ANDA products pursuant to a royalty-bearing license as early as December 11, 2017, or sooner under certain conditions, subject to FDA approval. All other terms and conditions of the settlement and license agreement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission. For the 12 months ending Dec. 31, 2014, Viagra had U.S. sales of approximately $1.3B, according to IMS Health.
April 9, 2015
09:51 EDTPFEPerrigo did not expect Mylan takeover letter, CNBC's Faber reports
Perrigo (PRGO) did not expect the takeover letter it received from Mylan (MYL), CNBC's David Faber reports, citing sources. Perrigo will take its time in deciding what its next steps are, Faber added. Shares of Mylan are up 3% in early trading, which is being attributed, at least in part, to speculation the company could be a takeover target itself. Analysts this morning mentioned Teva (TEVA) as a potential acquirer of Mylan. Chatter this morning has Pfizer (PFE) also potentially interested in the EpiPen maker
09:25 EDTPFEPiper Jaffray pharmaceuticals analysts hold an analyst/industry conference call
Subscribe for More Information
08:04 EDTPFEPfizer launches PCSK9 competitive grants program
Subscribe for More Information
April 8, 2015
11:23 EDTPGProcter & Gamble starts sale process for beauty brands, Bloomberg says
Procter & Gamble (PG) has begun the sale process for its Wella haircare unit, some cosmetics brands and its fragrance business by sending out documents to potential bidders, according to Bloomberg, citing people familiar with the matter. Potential buyers contacted include Revlon (REV), Unilever (UN, UL), Coty (COTY), Kao Corp. and Henkel, the report noted, adding that the businesses could fetch as much as $19B altogether. Reference Link
April 7, 2015
08:09 EDTPFEPfizer, Merck KGaA finalize agreement to co-promote XALKORI
Merck KGaA (MKGAY) and Pfizer (PFE) announced the finalization of the co-promotion agreement allowing the companies to co-promote Pfizerís anaplastic lymphoma kinase inhibitor XALKORI. Under the agreement, XALKORI will be co-promoted in two waves, the first of which will begin in the second and third quarters of 2015 in the United States, Canada, Japan and five European Union countries: France, Germany, Italy, Spain and the United Kingdom. In the U.S. and Canada, XALKORI will be co-promoted by EMD Serono, the U.S. and Canadian biopharmaceutical businesses of Merck KGaA. The second wave will begin in 2016 and includes China and Turkey. n 2015, Merck KGaA will receive a reimbursement associated with its promotion of XALKORI, followed by an 80% for Pfizer, 20% for Merck KGaA profit sharing on the product starting in 2016. The co-promotion term will last through December 31, 2020 for the U.S., Canada, Japan, France, Germany, Italy, Spain and the U.K. and from January 1, 2016 through December 31, 2021 in China and Turkey. Pfizer will report the sales of XALKORI in countries where it is co-promoted with Merck KGaA.
07:14 EDTPFEEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
07:02 EDTPFEGlycoMimetics updates on Pfizer's plans to initiate Phase 3 Rivipansel trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use